Although it is now widely appreciated that antitumor immunity is critical to impede tumor growth and progression, there remain significant gaps in knowledge about the mechanisms used by tumors to escape immune control. In tumor cells, we hypothesized that one mechanism of immune escape used by tumors involves the synthesis and extracellular shedding of gangliosides, a class of biologically active cell surface glycosphingolipids with known immunosuppressive properties. In this study, we report that tumor cells engineered to be ganglioside deficient exhibit impaired tumorigenicity, supporting a link between ganglioside-dependent immune escape and tumor outgrowth. Notably, we documented a dramatic reduction in the numbers and function of tumorinfiltrating myeloid-derived suppressor cells (MDSC) in ganglioside-deficient tumors, in contrast with the large MDSC infiltrates seen in ganglioside-rich littermate control tumors. Transient ganglioside reconstitution of the tumor cell inoculum was sufficient to increase MDSC infiltration, supporting a direct connection between ganglioside production by tumor cells and the recruitment of immunosuppressive MDSC into the tumor microenvironment. Our results reveal a novel mechanism of immune escape that supports tumor growth, with broad implications given that many human tumors produce and shed high levels of gangliosides. Cancer Res; 74(19); 5449-57. Ó2014 AACR.
Introduction
The formation and progression of human cancer are influenced by multiple factors. Beyond the necessary intrinsic and autonomous proliferative capability of tumor cells, interactions with the tumor microenvironment (TME) are critical to the actual growth of tumors and contribute to resistance to therapy (1, 2) . These interactions in the TME can result from "signals" between tumor cells and the host in the form of soluble factors. The identification of novel tumor-derived factors and elucidation of their mechanisms of action that include, prominently, inhibition of effective antitumor immune responses, are important for developing new strategies to effectively intervene in impeding tumor progression.
Tumor cell gangliosides, biologically active, amphipathic molecules that are shed into the TME at a rapid rate (3) and by many tumors (4) are one such factor. Clinical correlations link ganglioside shedding and human tumor progression (5) . Two experimental approaches-impeding tumor growth by transient pharmacologic depletion of gangliosides (6) and enhancing tumor growth by enrichment of the TME by addition of exogenous gangliosides or of ganglioside-rich tumor cells (7)-further suggested that the presence of gangliosides in tumor cells and their microenvironment accelerate tumor growth. However, the mechanism(s) by which the natural, ongoing, continuous process of ganglioside synthesis and shedding by tumors enhances tumor growth have been unclear. This critical gap in understanding contrasts to the mostly in vitro identification of a number of properties of gangliosides that could impact the process of tumor formation in vivo, including upregulation of some microenvironmental processes that can promote tumor growth (e.g., fibroblast proliferation and tumor angiogenesis; refs. [8] [9] [10] [11] and the inhibition of others (e.g., antitumor immune responses; refs. 3, 12, 13) .
Addressing the issue of inhibition of the immune response, here we have identified myeloid-derived suppressor cells (MDSC) as being driven in their accumulation and function by the presence of gangliosides in the tumor cells and their microenvironment. Because tumor infiltrating MDSCs are now known to have many functions, including directly inhibiting antitumor cellular immune responses (14) (15) (16) , recruiting regulatory T cells (17) , and inhibiting CD8 þ effector T-cell infiltration (18) , the findings may explain how gangliosides allow tumors to effectively subvert antitumor immune responses in vivo.
Materials and Methods

Mice and reagents
All animal experiments were approved by the Children's National Medical Center Institutional Animal Care and Use Committee (Washington DC). C57BL/6 and NOD-Rag1 À/À mice (female, 6-8 weeks old) were purchased from The Jackson Laboratory and were housed in specific pathogen-free units. MDSC isolation kits were obtained from Miltenyi Biotech. For flow cytometry, monoclonal antibodies anti-Gr-1 (RB68C5), anti-Ly-6C (AL21), anti-Ly-6G (1A8), anti-CD11b (M1/70), and anti-CD45 (F11-30) were from BD Biosciences. 1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (PPPP), >98% pure by high-performance thin-layer chromatographic (HPTLC) analysis was gift from Matreya, Inc.
Tumor cells
DKO (Ras/Myc-transformed GM3S/GM2S double knockout mouse embryonic fibroblasts) and wild-type (WT; transformed littermate control WT mouse embryonic fibroblasts; ref. 19) were cultured in DMEM medium supplemented with 10% FBS, 2 mmol/L L-glutamine, and 1% minimum nonessential amino acids. EL4 murine lymphoma cells were maintained in DMEM supplemented with 10% FBS. All cells cultures were maintained in an atmosphere of 5% CO 2 /95% air in a humidified incubator at 37 C.
Tumor cell ganglioside radiolabeling, isolation, and HPTLC analysis of shedding C]-galactose for 24 hours and then washed. After an additional 24 hours in culture in complete medium, the total radiolabeled gangliosides of the cells and those shed into the culture supernatant were purified and analyzed by HPTLC autoradiography as described (3) . Briefly, the total lipid extracts were partitioned in DIPE/1-butanol/saline and total gangliosides (lower aqueous phase) were further purified by Sephadex G-50 gel filtration. HPTLC analysis was performed using 10 Â 20 cm precoated silica gel 60 HPTLC plates (Merck) developed in chloroform/methanol/0.25% aqueous CaCl 2 .2H 2 O (60:40:9, v/v/v) and visualized by autoradiography to detect shed gangliosides. Unlabeled gangliosides from WT cells were isolated and purified by the same methods, and then dissolved in PBS for use in the reconstitution experiments.
Inhibition of glucosylceramide synthase in EL4 cells by PPPP PPPP was prepared as a 1 mmol/L stock solution in ethanol, stored at 4 C, and diluted to a final concentration of 0.5 mmol/L in culture medium with 1% ethanol. EL4 cell cultures were incubated for 5 days in PPPP or in 1% ethanol alone, harvested, and washed before injection.
Tumor formation
Ganglioside-depleted DKO tumor cells and WT tumor cells in 20 ml PBS were injected s.c. (10 4 or 10 5 cells) in C57BL/6 or NOD-Rag1 À/À mice. A total of 1 Â 10 6 EL4 or PPPP-treated EL4 tumor cells were injected s.c. in syngeneic C57BL/6 mice. Tumor growth was monitored with a digital caliper (length, width, and height) every 2 to 3 days. At the indicated times, mice were euthanized and tumors, and in some experiments lymph nodes, were excised and processed for analysis.
Preparation of tumor single cell suspensions Tumors were minced into small 2 Â 2 mm pieces and transferred into gentleMACS C Tubes containing 5 mL of RPMI-1640 medium, 300 U/mL Collagenase I, and 0.96 mg/mL Dispase II. The tubes were incubated for 20 minutes in a 37 C water bath with mixing to resuspend settled tissue fragments and then attached onto the sleeve of the gentle-MACS Dissociator and run using the appropriate program followed by further incubation for 20 minutes at 37 C in a water bath. Then, 100 U/mL DNase I was added to the tube, which was run on the Dissociator again. Finally, 10 mL PEB buffer was added to the tubes, which were centrifuged at 300 Â g for 10 minutes at 4 C. Red blood cells were removed by resuspending the pellet in 2 mL of ACK lysis buffer, followed by washing, resuspension in PBS, filtration through a 70 mm cell strainer, layering on Lympholyte M, and centrifugation at 400 Â g for 20 minutes at room temperature. Cells at the opaque interface were transferred into fresh tubes, washed twice with PBS, and analyzed.
Flow cytometry
Cells were washed in PBS and stained with Live/Dead Fixable Aqua stain (Invitrogen) for 30 minutes in the dark followed by washing with FACS wash buffer (PBS containing 05% FBS, 2 mmol/L EDTA, and 0.1% sodium azide). As a positive control for dead cell staining, 5 Â 10 5 cells were treated with heat at 65 C for 2 minutes, placed on ice for 2 minutes, and mixed with equal number of live cells. Singlecell suspensions were incubated with TruStain FcX antibody (BioLegend) to block Fc receptors and then stained with directly conjugated antibodies (BD Bioscience; BioLegend). Flow-cytometric analysis was performed on a FACSCanto (BD Biosciences) and 100,000 events were recorded for each sample. Data were analyzed using FACS Diva and FlowJo software (Tree Star). Gating was on Aqua Viability Stain negative CD45 positive populations, in which further markers were analyzed.
MDSC isolation
The single cell suspensions of tumors were adjusted to 10 8 cells in 900 mL of PEB buffer containing 1% FBS. Of note, 50 mL of Gr-1(PE)/CD11b(APC)/CD45(FITC) IgG3 were then added. The cells were incubated for 30 minutes at 4 C, centrifuged at 330 g for 10 minutes, and the cell pellets resuspended at 2.5 Â 10 7 /mL in ice-cold degassed HBSS containing 10 mmol/L HEPES and 2% FBS. The stained cells were sorted using the Influx cell sorter (BD Biosciences). MDSC (CD11bþ/Gr1þ) were collected after gating on the live CD45 þ population, centrifuged, resuspended in HL-1 culture medium, and irradiated (2.5 gy) immediately before use in the OT-1 splenocyte proliferation assay. Purity of the sorted CD11bþ/Gr-1þ cells was >90%.
Inhibition of T-cell proliferation and IFNg secretion by MDSC Splenocytes from OT-1 mice were prepared by dissociation using frosted-end slides, seeded in 96-well plates, and cultured for 96 hours at 37 C HL-1 medium with 1% penicillin, 1% streptomycin, 50 mmol/L 2-ME, and 2 mmol/L glutamine, with 0.01 mg/mL OVA peptide (SIINFEKL, 257-264) or control peptide E7 (RAHYNIVTF, 49-57). The cells were pulsed with 1 mCi 3H-thymidine/well during the last 18 hours, harvested, and 3H-thymidine uptake determined. The secretion of IFNg was quantified in supernatants OT-1 splenocyte/MDSC cultures collected on day 4. IFNg was assayed by ELISA.
Statistical analysis
Changes in tumor incidence with time were analyzed by the log-rank test. Changes in MDSC with tumor size and time of tumor growth were analyzed by longitudinal linear regression analysis to account for the correlation between repeated assessments over time. All bars shown in the figures represent mean AE SEM values. Statistical significance was calculated using the two-tailed Student t test.
Results and Discussion
The model
The experimental system we used to determine how immunologic mechanisms are influenced in vivo by de novo ganglioside synthesis and shedding is a novel tumor cell created by oncogenic transformation (pBABE-c-Myc
T58A þ H-Ras G12V ) of murine embryonic fibroblasts in which two enzymes, GM3 synthase and GM2 synthase, that together specifically control all ganglioside synthesis in these mice had been knocked out (19) . Ganglioside synthesis in these DKO cells was thereby constitutively and completely blocked, in contrast with the robust ganglioside synthesis of similarly derived littermate control WT tumor cells. This knockout renders the tumor cell completely devoid of the gangliosides (GM3, GM2, GM1, and GD1a) that are present in the WT cells (19) . Only mild (less than one-fold) elevations of the ganglioside precursor molecules lactosylceramide (36%), glucosylceramide (65%), and ceramide (30%) accompanied this complete blockade of ganglioside synthesis (19) . Earlier studies with the DKO cells (19) showed that the absence of gangliosides in the tumor cell was associated with markedly impeded tumor growth in syngeneic mice despite robust, unaltered proliferation kinetics of the DKO cells in vitro.
This system has enabled us to explore here a suspected relationship between active tumor cell ganglioside metabolism and subversion of antitumor immune responses. We first confirmed by autoradiography that the genetic deletion of ganglioside synthesis by DKO tumor cells is accompanied by abrogation of the release of tumor cell gangliosides into the culture supernatant (Fig. 1A) . Thus, alterations in immune responses observed in DKO tumor-bearing mice, compared with responses in WT tumor-bearing mice, would be directly linked to the interrupted ganglioside metabolism of the tumor cell.
Ganglioside-deficient DKO tumor growth is accelerated in immunosuppressed mice
To test the hypothesis of a causal relationship between the absence of gangliosides and decreased tumor growth, and the role of antitumor cellular immune responses, we probed the possibility of a direct immunologic effect of the presence or absence of tumor cell gangliosides on tumor growth. Here, we (Fig. 1B, right ) was now increased from 50% to 100% (P < 0.001). This was the same incidence as that of the WT cells. Moreover, in NOD-Rag1 À/À mice, the rate of growth of these ganglioside-poor DKO tumor cells was substantially accelerated, almost that of the WT cells (Fig. 1C, right) . The rate of growth of the WT cells was not significantly different in normal versus immunodeficient mice (P ¼ 0.5). Comparing WT cell tumor growth in normal C57Bl/6 versus immunodeficient NOD-Rag1 À/À mice, 10 4 DKO cells reached a tumor volume of 500 mm 3 in 22 days in the immunodeficient mice versus 43 days in the immunocompetent mice (P < 0.0001). The increased incidence and faster growth of ganglioside-poor (DKO) tumors in immunodeficient mice support the suggestion that tumor gangliosides accelerate tumor growth by interfering with cellular immune responses that normally might control tumor growth.
Tumor cell gangliosides influence immune cell and MDSC infiltration of tumors
As the next step, we analyzed ganglioside-deficient DKO tumors and ganglioside-replete WT tumors for infiltration by T cells, which mediate antitumor cellular immune responses and may control tumor growth, progression, and rejection (21) . Total CD45 þ leukocyte infiltration was more than 2-fold higher in DKO than in WT tumors (18.0 Â 10 4 vs. 7.1 Â 10 4 CD45
þ cells/10 6 tumor cells, or 20% vs. 7.5% of total cells in the tumor). Both CD4 and CD8 T lymphocyte subsets were nearly 4-fold higher in the DKO tumors (Table 1) . We also quantified these cells in tumor draining lymph nodes (TDLN) where they are critical in effecting antitumor immune responses. Significantly higher numbers of CD4 and CD8 T cells were detected in the TDLN of ganglioside-poor DKO tumor-bearing mice than in the TDLN of ganglioside-rich WT tumor-bearing mice (Table 1) , again suggesting increased effective immune responses result when tumors are ganglioside deficient.
Using a directed approach to further probe suppression of the cellular immune response, we focused on the myeloid compartment and specifically on MDSC for several reasons: (i) MDSCs that infiltrate the TME inhibit antitumor cellular immune responses (14-16), recruit regulatory T cells (17) , and inhibit CD8
þ effector T-cell infiltration (18) (14, 25) , and that we observed in the ganglioside-rich WT tumors, was not seen in the DKO tumors ( Fig. 2E , P ¼ 0.009). With respect to tumor growth as a function of time from cell inoculation, the best longitudinal model of tumor growth over a 30-day period indicated a curvilinear growth pattern in degree of MDSC infiltration with a peak at 14 days, with consistently greater infiltration in WT tumors compared with DKO tumors (P < 0.001, Fig. 2F ). The relative proportions of the two major currently recognized subsets of MDSC (16, 26) , the predominant, granulocytic, G-MDSC (Ly6G þ Ly6C dim ), and the monocytic Mo-MDSC (Ly6G dim Ly6C high ) were not significantly affected by the absence of gangliosides in the DKO tumors (Fig. 2D) . Overall, the results suggest for the first time that gangliosides in tumors have a striking impact on the total number of tumor-infiltrating MDSC. They implicate tumor-associated gangliosides in facilitating MDSC accumulation and their absence to result in markedly reduced numbers of MDSC in the tumors.
We also tested whether the accumulation of MDSC in tumors under the influence of tumor gangliosides was linked, to or dependent on, lymphocyte interactions or whether MDSC accumulation is independent of adaptive immune responses, as has been suggested (22) . We did this by inoculating tumor cells into the immunodeficient mice and quantifying tumorinfiltrating MDSC (Fig. 3 Fig. 4B ). And, as assessed by FACS (Fig. 4A) , the number of tumor-infiltrating MDSC and MDSC numbers ( Fig. 4C and D) , evidenced a more than 3-fold increase from 5 AE 1 Â 10 4 MDSC/tumor (7.5% of CD45 þ cells) to 18 AE 6 Â 10 4 MDSC/tumor (11% of CD45 þ cells; P ¼ 0.03) without significant changes in MDSC subset proportions (Fig. 4E ).
In the second approach, before injection in syngeneic mice, we incubated ganglioside-rich EL4 murine lymphoma cells with PPPP to inhibit glucosylceramide synthase. This treatment blocks all ganglioside synthesis and causes complete but only transient ganglioside depletion (27) . The treated cells evidenced a trend toward reduced tumor growth in vivo, which although not statistically significant, was seen as a reduction in tumor mass at 9 days (Fig. 5A) , to 214 AE 32 mg from 338 AE 73 mg of the control ganglioside-rich EL4 cells (P ¼ 0.15).
Although we did not observe a change in intratumor T-cell numbers, this is possibly because unlike constitutive ongoing inhibition of ganglioside synthesis in the DKO cells, inhibition by PPPP pretreatment of tumor cells is only transient (several days at most; ref. 27 ), thereby possibly resulting in milder effects overall (on tumor growth, on MDSC, and by implication, on T-cell numbers). Importantly, the absolute number of MDSC in the ganglioside-depleted tumors was markedly reduced (Fig. 5B) , from a mean of 83 Â have been shown to have potent inhibitory activity in many tumor systems (16), so we determined whether the reduction in the number of MDSC infiltrating the ganglioside-deficient DKO tumors was accompanied by a change in the level of their immunosuppressive activity. We assessed MDSC enriched by FACS from single cell suspensions of WT and DKO tumors for their ability to inhibit antigen-specific T-cell responses. Splenocytes from OT-1 T-cell receptor transgenic mice were stimulated with either the cognate (OVA-257) antigen or a control peptide (E-7) and were cultured in the presence of irradiated MDSC isolated either from WT control or from DKO tumors (22) . Inhibition by the MDSC of OT-1 T-cell antigen-specific proliferation (14) and release of IFNg (28) were quantified. MDSC isolated from control WT tumors were twice as effective as MDSC isolated from ganglioside-deficient DKO tumors in inhibiting the antigeninduced proliferative response of OT-1 splenocytes (Fig. 6A ). Similar to their inhibitory effect on the proliferative response, MDSC isolated from WT tumors also markedly inhibited OT-1 cell IFNg production. In contrast, MDSC isolated from DKO tumors were essentially unable to inhibit OT-1 splenocyte IFNg release either at the optimal time point (Fig. 6B) or over a time course (Fig. 6C) . Thus, in addition to markedly reduced numbers of MDSC infiltrating the ganglioside-deficient DKO tumors, those MDSCs that were infiltrating the tumors were functionally impaired. Overall then, we have shown that the synthesis and shedding of tumor cell gangliosides modulate both MDSC accumulation and MDSC activity in the resulting tumors. Tumor gangliosides are unusual molecules that, based on many in vitro and indirect in vivo findings, are assumed to be important in vivo. With relatively mild effects on their tumor cells of origin, gangliosides expressed and shed by these cells may profoundly affect "normal" stromal cells to which they can become bound in the TME although until now, whether they have a biologically significant effect on the antitumor immune response in vivo had been unclear. Benefitting from a novel model system, here we discovered that tumor gangliosides are in fact a potent immunoregulatory factor, promoting the tumor infiltration and activity of MDSC.
Although the absence of tumor cell gangliosides clearly reduces tumorigenicity and tumor growth, ganglioside blockade does not completely arrest the growth of tumors once they are established. DKO tumors nevertheless eventually grow even without developing high numbers of MDSC. And, neither implantation of DKO cells in NOD-Rag1 À/À mice nor ganglioside addback to DKO cells implanted in immunocompetent mice yields complete recovery of growth and MDSC numbers. On the basis of our findings, we think that in our model, the effect of tumor gangliosides on the host immune response played a key role in the initial of steps successful tumor cell implantation and growth. Without this advantage, that is, lacking gangliosides, DKO tumors that did form grew slowly initially but then eventually enlarged, most likely through the support of other tumor-promoting factors, such as other tumor cell-derived stimulants of angiogenesis, or gradual accumulation in tumors of gangliosides derived from host cells that infiltrate tumors.
Discovery of a relationship between tumor gangliosides and MDSC raises a number of important questions to be addressed in future studies, particularly about the mechanisms by which the gangliosides are acting. This includes elucidating how MDSC accumulation is enhanced by gangliosides (possibly by chemokine/chemokine receptor expression, for example). Also, what mechanisms underlie the observed difference caused by gangliosides in the expression of inhibitory function of MDSC? These could include a specific effect on molecules that are known to cause the MDSC-induced immunosuppression, for example, iNOS and arginase and their products, or the possibility that gangliosides directly affect MDSC activation through contact in the TME.
This novel immunoregulatory mechanism of tumor gangliosides-inhibition through enhancement of MDSC number and their function in tumors-is complemented by direct inhibitory effects of gangliosides on cytotoxic T-cell function (29) , suggesting a highly effective immunosuppressive process that tumors may use early on to implant and establish themselves, and a process that links rapid ganglioside metabolism to enhanced tumor growth. The deficit of infiltrating MDSC in ganglioside-poor DKO tumors may also in part explain the negative impact that the absence of gangliosides has on another process important to tumor growth, angiogenesis (30) . In this case, it is tempting to speculate that because MDSCs directly promote tumor angiogenesis (31) and the poorly vascularized, poorly growing ganglioside-poor DKO tumors have greatly reduced angiogenesis (30), tumor accumulation of MDSC (dependent on the presence of tumor gangliosides) is an "effector mechanism" that is at least in part also responsible for ganglioside enhancement of tumor angiogenesis.
Overall, our findings establish tumor cell gangliosides as an important immune evasion factor with potential broad significance because rapid ganglioside synthesis and shedding characterize many tumor types. Consequently, therapeutic strategies to impede tumor cell ganglioside metabolism, such as specific inhibition of their synthesis by tumor cells, could be a promising approach to pursue to improve cancer treatment.
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